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Objective: Evidence on the efficacy of Nigella sativa supplementation is equivocal, thus the 
aim of this systematic review and meta-analysis of randomized clinical trials (RCTs) was to 
examine the effect of Nigella sativa (N. sativa) supplementation on plasma C-reactive protein 
(CRP) concentrations. 
Methods: PubMed, Scopus, ISI Web of Science, Cochrane library, and Google Scholar 
databases were searched (up to April, 2019) to identify RCTs investigating the effects of N. 
sativa seed and seed oil supplementation on CRP. Weighted mean differences (WMD) was 
pooled using a random-effects model. Standard methods were also used for assessment of 
heterogeneity, sensitivity analysis, and publication bias. 
Results: Eventually only five articles which reported data of interest entered for data 
analysis. The meta-analysis showed a significant reduction in serum CRP (WMD: -0.55 
mg/L, 95% CI: -1.02, -0.08, P=0.02), with significant heterogeneity between selected studies 
(I2=77.3%). Between-study heterogeneity disappeared following subgroup analysis, stratified 
by baseline BMI (≥30 kg/m2: I2=2.8%). However, the effect of N. sativa seed and seed oil 
supplementation on CRP was only significant in studies that were conducted on participants 
with BMI≥30 kg/m2 (WMD: -0.50 mg/L, 95% CI: -0.85, -0.15). 
Conclusions: This meta-analysis suggests that N. sativa seed and seed oil supplementation 
can significantly reduce serum CRP level. However, RCTs with a larger sample size and 
longer follow-up periods should be conducted for future investigations to confirm the 
veracity of these results. 




C-reactive protein (CRP) is an acute phase protein produced by liver, and its concentration is 
notably increased during infections and inflammation 1. CRP is classified as first-line defence 
molecule against pathogenic organisms, particularly given its affinity for binding to 
phosphocholine of bacterial and fungal membranes 1, 2. It also functions to stimulate 
phagocytic cells that remove apoptotic and necrotic cells, further contributing to the healing 
of injured tissues 2, 3. Production of CRP from the liver is stimulated by cytokines associated 
with non-specific tissue injury, including; interleukin-1β, interleukin-6, and tumor necrosis 
factor alpha (TNF-α) 3, 4. It has been shown that CRP levels in apparently healthy humans 
may predict future risk for cardiovascular disease (CVD), independent of established risk 
factors. Moreover, serum CRP has been purported to predict incidence of myocardial 
infarction, coronary artery disease (CAD), stroke, peripheral arterial disease, and sudden 
death; concomitant to acting as a mediator of these conditions 5-7. Whilst such non-
communicable diseases are commonly treated by pharmacotherapies, the concept of 
complementary medicine is proliferating, with a reputed 80% of the global population 
utilising complementary therapies 8, 9.  
Medicinal plants may serve as an adjuvant in the treatment and prevention of various non-
communicable diseases as they contain a wide range of bioactive phytochemicals with 
diverse metabolic effects, and, moreover, have been asserted as safe adjuvant treatments to 
reduce the progression, morbidity as well as the cost of treatment 10-12. One such example is 
Nigella sativa L. (N. sativa), commonly known as black seed, which belongs to the botanical 
family of Ranunculaceae 13, 14. N. sativa has been traditionally in use in many Middle and Far 
East countries as a natural remedy for a wide range of illnesses, attributed to its wide range of 
pharmacological properties 14. Among the active ingredients of N. sativa, thymoquinone (TQ) 
4 
 
is one of the most important ingredients, which purportedly contains anti-oxidant, anti-
inflammatory and immunoprotective properties 15-17. 
Although some evidence exists to support the use of N. Sativa seed and seed oil to positively 
influence CRP 12, 18-20, the current evidence base is bereft of uniformity, and given the 
absence of a unifying and elucidatory analysis, we sought to systematically review and meta-
analyse the effect of N. Sativa seed and seed oil supplementation on serum CRP in humans. 
Methods 
The present systematic review was planned, conducted, and reported in adherence to the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) 
guidelines21. 
Search strategy 
Five databases, including PubMed (http://www.ncbi.nlm.nih.gov), Scopus 
(http://www.scopus.com), Cochrane Library (http://www.cochranelibrary.com), ISI Web of 
Science (http://www.webofscience.com) and Google Scholar (http://scholar.google.com) 
were explored with no language or time frame restriction up to April, 2019. The search 
strategy was drawn up using following keywords and medical subject heading (MeSH) terms: 
“Nigella sativa” OR “black seed” OR “kalonji” OR “black cumin” OR “black caraway” 
combined with “C-Reactive Protein” OR “high-sensitivity CRP” OR “hs-CRP” OR “CRP”. 
In addition, we manually reviewed reference lists from the retrieved articles, systematic 
reviews, and meta-analyses to avoid missing any pertinent articles. 
Study selection 
EndNote software, version X6 (Thomson Reuters) was used for record management. After 
removing duplicates and publications without an English abstract, the remaining articles were 
independently screened by two authors (A.H and A.A) based on the title and abstract and 
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irrelevant records, animal studies and reviews were excluded. Then, the full text of remaining 
articles was investigated profoundly to choose only related studies. Finally, all 
randomized controlled trials (RCTs) (either parallel or cross-over designs) that examined the 
effects of N. sativa seed and seed oil supplementation on CRP in adults (age≥18-year old) 
were selected. Studies that prescribed N. sativa mixed with other substances, publications 
with duplicate data, and also trials without an appropriate control group were excluded. 
Disagreement between reviewers was resolved by discussion or, if it was necessary, by 
consulting with a third reviewer (E.Gh). 
Data extraction 
Two investigators (A.H and A.A) abstracted relevant data from the selected trials. This 
process was verified by another investigator (E.Gh). The following methodological and 
outcome variables from each included papers were extracted, using a data abstraction form: 
first author’s last name, publication time, country in which the study was performed, research 
design, participant characteristics (mean age, gender and body mass index [BMI]), sample 
size, intervention duration (week), type and dose of supplements/placebo used in 
intervention/control group, and the main results. When results were presented in multiple 
time points, only data relating to the longest duration of treatment were considered. 
Quality assessment 
The methodological quality of enrolled studies was assessed using the scoring system 
developed by Jadad et al.22, where total score ranges 0 to 5 points based on the 5 items: 1) 
randomization, 2) methods of randomization, 3) blinding, 4) suitable method of double 
blinding, and 5) withdrawn or drop-outs explanation. The scores of 3 or more represented 
high quality while 0-2 indicated a low-quality study. This section was also independently 
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accomplished by two researchers (A.H and A.A). Final scores were discussed by the 
investigators to make a consensus. 
Statistical analysis 
The pooled weighted mean difference (WMD) and its 95% confidence interval (CI) were 
estimated to assess the effects of N. sativa on levels of serum CRP. In studies in which the net 
changes were not directly reported, the WMD was calculated by following formula: (measure 
at the end of follow-up in the treatment group - measure at baseline in the treatment group) - 
(measure at the end of follow-up in the control group - measure at baseline in the control 
group). Also, the standard deviation (SD) of WMD was calculated as follows: [SD=square 
root [(SD pre-treatment) 2 + (SD post-treatment) 2 - (2R × SD pre-treatment × SD post-
treatment)], assuming a correlation coefficient of 0.5. To ensure that our meta-analysis was 
not sensitive to the selected correlation coefficient, all the analyses for each parameter was 
repeated using a correlation coefficient of 0.2 and 0.8. In the case that standard error (SE) of 
mean was only reported, SD was calculated using the following formula: SD= SE × square 
root (n), where n is the number of participants in each group. All meta-analyses were done 
using the random effects model which takes the between-study variability into account. The 
presence of between-study heterogeneity was assessed by the I2 statistic. Low, moderate and 
high heterogeneity was ascribed to I2 values less than 25%, between 25-50% and over 50%, 
respectively 23. To find the potential sources of between-study heterogeneity, we carried out a 
pre-planned subgroup analysis based on based on baseline BMI (≥30 or ˂30 kg/m2), N. sativa 
dosage (≥2 or ˂2 mg/day), and intervention form (powder or oil). Heterogeneity between 
subgroups was evaluated using a fixed-effect model. Sensitivity analysis was also executed in 
order to evaluate the influence of every single study on the overall effect size. Publication 
bias was evaluated using visual assessment of funnel plots and Egger's weighted regression 
tests24. All analyses were carried out using the STATA software (version 11.2, Stata Corp, 
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College Station, TX, USA) and two-sided p-values < 0.05 were considered statistically 
significant. 
Results 
Flow of study selection 
Study selection and identification process are depicted in Figure 1.  A total of 95 publications 
were identified using the search strategy previously described in the method part, from which 
31 were excluded after duplicate deletion. By reviewing the title and abstracts of the 
remaining articles, 54 publications which were irrelevant to the study objectives were 
excluded.   Subsequently, 10 full-text articles were carefully reviewed for eligibility and 3 
clinical trials were excluded because of the following reasons: two studies had interventions 
using other components in addition to N. sativa, and one article included a duplicate 
population. Finally, 7 eligible trials 12, 18-20, 25-27 were considered eligible for the systematic 
review. However, two of the included articles 25, 26 did not report the data required for meta-
analysis. We contacted the corresponding author of studies, twice, but did not receive any 
response. These 2 studies were therefore excluded, leaving 5 studies 12, 18-20, 27 for inclusion in 
the meta-analysis. 
Study and participant characteristics 
Details characteristics of the included trials are outlined in Table 1. In total, 439 participants 
were enrolled in selected articles, of which 222 individuals allocated to N. sativa 
supplementation group and 217 subjects to the control group. These studies were published 
between 2010 and 2019 and were carried out in the Iran18-20, 26, 27, Pakistan 12, and Indonesia 
25. All studies except one 26 adopted a parallel study design. The mean age of the participants 
ranged from 37.02 to 47.48 years old and mean baseline BMI varied from 24.60 to 32.05 
kg/m2.  Only, one out of included studies 25 was conducted exclusively in men, two in women 
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18, 19, and the other trials12, 20, 26, 27 were performed in both genders. The follow-up period 
ranged from 6 to 12 weeks. Daily recommended dosage of N. sativa-based natural products 
varied between 1 and 3 g/day in these studies, including both crushed seeds and seed oil. 
 Included studies were carried out in various populations, including metabolic syndrome 12, 26, 
obese individuals 19, 25, rheumatoid arthritis 18, ulcerative colitis 27, and non-alcoholic fatty 
liver disease (NAFLD) 20. 
Quality assessment 
The Jaded checklist showed that all studies except one 25 had high methodological quality. 
The details of quality assessment in individual studies are provided in Table 2. 
Findings from the systematic review 
Based on the present systematic review, 4 trials reported reduced CRP level with N. sativa 
seed and seed oil supplementation 12, 18-20, while 2 studies did not find such an effect 25, 26. 
Moreover, a significant increase in the levels of serum CRP was observed following N. sativa 
seed and seed oil supplementation in one of the trials 27. 
Findings from the meta-analysis 
The forest plot displaying the effect of N. sativa seed and seed oil supplementation 
supplementation on circulating CRP is demonstrated in Figure 2. The pooled estimate from 
the random-effect model that performed on 5 studies including 175 cases and 173 controls, 
showed N. sativa seed and seed oil supplementation significantly reduced CRP 
concentrations (WMD: -0.55 mg/L, 95% CI: -1.02, -0.08, P=0.02). As there was a significant 
heterogeneity (P˂0.001, I2=77.3%), we performed subgroup analysis and found that baseline 
BMI (≥30 kg/m2: P=0.31, I2=2.8%) could explain between-study heterogeneity. However, the 
effect of N. sativa seed and seed oil supplementation on CRP was only significant in studies 
that were conducted on participants with BMI≥30 kg/m2 (WMD: -0.50 mg/L, 95% CI: -0.85, 
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-0.15, I2=2.8%). In another subgroup analysis by intervention forms, N. sativa powder subset 
showed non-significant differences in the mean change of CRP which is in contrast with the 
overall results. The subgroup analysis by dose of intervention did also not show any 
significant difference in the mean change of circulating CRP (Table 3). 
Moreover, the sensitivity analysis demonstrated that with the removal of the study by 
Mahdavi et al. 19 and Amin et al. 12 the effect of N. sativa on CRP became non-significant 
(WMD: -0.53 mg/L, 95% CI: -1.17, 0.10, P=0.41 and WMD: -0.56 mg/L, 95% CI: -1.23, 
0.10, P=0.39, respectively).  
Publication bias 
Assessment of publication bias by visual inspection of funnel plot indicated no evidence of 
publication bias in the meta-analysis of N. sativa supplementation on circulating CRP 
concentrations (Figure 3). Egger's linear regression test also showed the same result 
(P=0.77). 
Discussion 
The present meta-analysis included a total of 439 adults presenting with NAFLD, metabolic 
syndrome, obesity, ulcerative colitis and rheumatoid arthritis from 7 RCTs. Despite 
considerable heterogeneity among the studies, our findings indicate improvement in the 
levels of serum CRP following N. sativa seed and seed oil supplementation. To our 
knowledge, this is the first systematic review that has assessed the effects of N. sativa on 
serum CRP. Significant reductions in serum CRP levels by −0.55 mg/L were observed 
following N. sativa seed and seed oil supplementation with no detectable changes in the 
control group.  
Reductions in the levels of serum CRP, as observed in the present study, are important in the 
clinical setting, because levels ≥ 3 mg/dL are related to increases in the risk of coronary heart 
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disease by up to 58%28, 29. CRP, and particularly hs-CRP, is one of the most frequently used 
biomarkers for assessing the inflammatory status, with predictive values for various chronic 
diseases including CVD. Since metabolic syndrome is considered a chronic mild 
inflammatory state, levels of acute-phase reactants are usually elevated among patients with 
it30-32. In this meta-analysis, patients with metabolic syndrome, or the hepatic component of 
it, i.e. NAFLD, and obesity were mainly included. Therefore, the chronic mild inflammatory 
state of the above-mentioned metabolic disorders could account for the association between 
the observed increases in CRP among those patients. On the contrary, when N. sativa seed 
and seed oil was administered, the observed significant decreases in CRP levels could be due 
to the anti-inflammatory properties of N. sativa. 
When we categorized studies based on dose, the result was non-significant in both subsets, 
which may be attributable to the lower number of trials included in each subgroup. In 
addition, the findings showed that CRP reduction was more pronounced when N. sativa was 
administrated as oil, suggesting that form of N. sativa is one of the important factors which 
affect CRP responses. Previous meta-analysis which investigating effect of N. sativa seed 
showed that N. sativa seed oil were more effective in lowering low density lipoprotein (LDL) 
and cholesterol 33 and glycaemic indexes34. Such differences have previously been attributed 
to the chemical composition and preparation process of N. sativa seed oil, as compared with 
seed powder that is prepared by crushing 35, 36. Some potential anti-inflammatory mechanisms 
of N. sativa seed in the most studies have been attributed to antioxidant activity 37. TQ and 
dithymoquinone are the major active antioxidant components of N. sativa 37. Actually 
controlled thermal processing of the N. sativa seeds, responsible for TQ accumulation at 
temperatures between 50 and 150°C; on the other hand TQ is fat soluble which can lead to 
higher biological activity of the TQ in the oil from 38, 39.  
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In subgroup analyses, we also found that N. sativa supplementation could reduce CRP levels 
in participants with baseline BMI≥30 kg/m2, a result which is not only interesting, but also 
important to emphasize. As we know, obese subjects have higher CRP levels than other 
people due to the accumulation of free fatty acid intermediates, which subsequently activate 
pro-inflammatory serine kinase cascades 40. Thus, it is logical that bigger changes in CRP 
concentration were manifest in subjects with baseline BMI≥30 kg/m2 
The anti-inflammatory properties of N. sativa have already been reviewed, and several 
mechanisms of action have been described. TQ, the major constituent of N. sativa or black 
seed or black cumin, possesses anti-inflammatory properties that prevent the biosynthesis of 
important mediators in inflammatory processes, such as cyclooxygenase (COX), 
prostaglandin-2 and leukotrienes41, 42. TQ has been also shown to reduce LPS-induced pro-
inflammatory cytokines, such as interleukins and TNF-α 43, 44.  
Numerous studies have been reported that N. sativa could improve body antioxidant defence 
through enhancement of antioxidant enzymes activity and reduction of reactive oxygen 
species 45, 46. Furthermore, it has been suggested that N. sativa supplementation, by 
scavenging various free radicals, including hydroxyl radicals, hypochlorous acid and singlet 
oxygen, suppresses inflammation and oxidative stress 15, 17. Besides, considering the positive 
role of weight loss in improving the CRP level, the beneficial effects of N. sativa on the CRP 
can be attributed to its anti-obesity activity 47, 48. 
Generally, N. sativa is known as a safe herbal medicine and no serious adverse effect was 
reported among included studies. However, there is antecedent reports that suggest N. sativa 
consumption can result in some unwanted side effects, such as; dyspepsia, nausea, allergic 
reaction, dermatitis, diarrhoea, abdominal cramping and slight anorexia in high dosages 33, 49. 
Furthermore, N. sativa is also known to adversely interact with both chemotherapy 
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medications and radiation therapy 50. Since it may act like an antioxidant in the body, this 
herbal supplement can decrease the efficacy of standard cancer treatments 50, 51.  
With respect to potential limitations in our study; first, a number of eligible studies in the 
present meta-analysis were relatively small which may have biased the results to some extent. 
Second, pathological status of participants was varied, including participants with with 
NAFLD, metabolic syndrome, obesity, ulcerative colitis and rheumatoid arthritis. Third, a 
high degree of heterogeneity was detected in both outcomes, and although we have explored 
the source of heterogeneity, the interpretation of findings may be influenced by the level of 
heterogeneity observed. Fourth, most of the included studies have been conducted in Iran, 
which makes it difficult to generalize the results to the rest of the world. Fifth, given the 
limited studies on each gender, duration of intervention and CRP type, we could not examine 
the effects of the aforementioned parameters. And finally, trials used various durations and 
doses with two different forms, although subgroup analyses were assessed the effects of seed 
oil and powder.  
Conclusion 
This meta-analysis suggests that N. sativa seed and seed oil supplementation in doses of 1g to 
3g daily can significantly reduce serum CRP level. This result may be attributable to the 
widely reputed anti-inflammatory properties of N. sativa seed and seed oil. However, RCTs 
with a larger sample size and a longer follow-up period should be considered in the near 
future in order to support the veracity these findings. 
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Legends of figures:  
Figure 1. PRISMA flow diagram of study selection process  
Figure 2. Forest plot of the effect of Nigella sativa supplementation on C-reactive protein 





Table 1. Characteristics of included studies 
 





Sample size  
 












(name and daily dose) 
Control  Results 
Datau et al 
(2010) 
Indonesia 40 Male 38 NR Parallel 
(Yes) 




Amin et al 
(2015) 




1500 mg/day of  N. sativa powder Placebo CRP ↓ 
 
Mahdavi et al 
(2016) 
Iran 90 Female 40.25 32.05 Parallel 
(Yes) 




Kheirouri et al 
 (2016) 









Mohtashami et al 
(2016) 




Wheat bread  + 3000 mg/day of  N. 
sativa powder 
Wheat bread hs-CRP ↔ 
 
 
Darand et al 
 (2019) 
Iran 43 Both 47.48 31.78 Parallel 
(Yes) 




Nikkhah-Bodaghi et al 
(2019) 









Table 2.  Methodological quality scores for the included studies using the Jadad scale. 
 
 
Study Randomization Methods of 
randomization 







Datau et al 
(2010) 
- - + - + 2 
Amin et al 
(2015) 
+ + + + + 5 
Mahdavi et al 
(2016) 
+ + + + + 5 
Kheirouri et al 
 (2016) 
+ - + + + 4 
Mohtashami et al 
(2016) 
+ + + + + 5 
Darand et al 
 (2019) 
+ + + + + 5 
Nikkhah-Bodaghi et al 
(2019) 
+ + + + + 5 
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Table 3. Result of subgroup analysis of included studies in meta-analysis. 




95% CI I2 (%) P for 
heterogeneity 
P for between 
subgroup 
heterogeneity 
Baseline BMI      0.88 
≥30 kg/m2 2 -0.50 -0.85, -0.15 2.8 0.31  
˂30 kg/m2 3 -0.64 -1.50, 0.23 87.9 ˂0.001  
N. sativa dose      0.04 
≥2 mg/day 3 -0.26 -0.74, 0.22 61.1 0.07  
˂2 mg/day 2 -1.04 -2.16, 0.07 88.0 ˂0.001  
Intervention type      ˂0.001 
Powder 3 -0.24 -0.65, 0.18 53.0 0.11  
Oil 2 -1.10 -2.11, -0.10 84.1 0.01  
1Calculated by Random-effects model  
































Articles identified through 
























Records after duplicates removed (n=64) 
Records screened (n=64) 
Articles removed by title/abstract 
(n=54) 
 
Full-text articles assessed for 
eligibility (n=10) 
Articles removed after full-text 
review (n=3): 
Studies that administrated 
arginine in combination with 
other components (n=2) 
Duplicate data (n=1) 
 
 
Included studies in qualitative 
synthesis (n=7) 
Included studies in 
quantitative synthesis (meta-
analysis) (n=5) 





NOTE: Weights are from random effects analysis
Overall  (I-squared = 77.3%, p = 0.001)
Kheirouri et al (2016)
Mahdavi et al (2016)
Nikkhah-Bodaghi et al (2019)
Study name
Amin et al (2015)
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